Structure for peptidase M14.003: carboxypeptidase B

Summary Gene structure Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Pharma

PDB	Organism	Resolution	Comment
1NSA	Sus scrofa	2.30 Å	precursor
The catalytic zinc is shown as a light grey CPK sphere. The zinc ligands are shown in ball-and-stick representation: His161 and His289 in purple, and Glu164 in dark blue. The propeptide is shown in grey.

		Show surface

TERTIARY STRUCTURE DATA
Comment	Resolution	PDB	PDBe	SCOP	CATH	PDBSum	Proteopedia	Reference
Bos taurus
fraction II	2.80 Å	1CPB	1CPB	1CPB	1CPB	1CPB	1CPB	Schmid & Herriott, 1976
procarboxypeptidase activation domain (NMR)	0.00 Å	1PBA	1PBA	1PBA	1PBA	1PBA	1PBA	Vendrell et al., 1991
Homo sapiens
precursor	1.60 Å	1KWM	1KWM	1KWM	1KWM	1KWM	1KWM	Barbosa et al., 2002
complex with tick carboxypeptidase inhibitor	2.09 Å	1ZLI	1ZLI	1ZLI	1ZLI	1ZLI	1ZLI	Arolas et al., 2005
Sus scrofa
precursor	2.30 Å	1NSA	1NSA	1NSA	1NSA	1NSA	1NSA	Coll et al., 1991
mature peptidase	1.40 Å	1Z5R	1Z5R	1Z5R	1Z5R	1Z5R	1Z5R	Adler et al., 2005
complex with 2-(5-[amino(imino)methyl]amino-2- chlorophenyl)-3-sulfanylpropanoic acid	1.75 Å	1ZG7	1ZG7	1ZG7	1ZG7	1ZG7	1ZG7	Adler et al., 2005
complex with (R)-2-(3-[amino(imino) methyl]aminophenyl)-3-sulfanylpropanoic acid	2.00 Å	1ZG8	1ZG8	1ZG8	1ZG8	1ZG8	1ZG8	Adler et al., 2005
complex with 5-[amino(imino)methyl]amino-2- (sulfanylmethyl)pentanoic acid	2.00 Å	1ZG9	1ZG9	1ZG9	1ZG9	1ZG9	1ZG9	Adler et al., 2005
complex with ( (2s)-5-amino-2-((1-N-propyl-1h- imidazol-4-yl)methyl)pentanoic acid) UK396,082 a tafia inhibitor	1.40 Å	2JEW	2JEW	2JEW	2JEW	2JEW	2JEW	Bunnage et al., 2007
complex with (s)-2-(3-aminomethyl-phenyl)-3-hydroxy- [(r)-2-methyl-1-(3-phenyl-propane-1-sulfonylamino)-propyl]- phosp	1.43 Å	2PIY	2PIY	2PIY	2PIY	2PIY	2PIY	Adler et al., 2008
complex with 2-(3-guanidino-phenyl)-3-[hydroxy-(3- phenyl-propyl)-phosphinoyl]-propionic acid	1.60 Å	2PIZ	2PIZ	2PIZ	2PIZ	2PIZ	2PIZ	Adler et al., 2008
complex with [((r)-1-benzyloxycarbonylamino-2-methyl- propyl)-hydroxy-phosphinoyloxy]-(3-guanidino-phenyl)- acetic acid	1.65 Å	2PJ0	2PJ0	2PJ0	2PJ0	2PJ0	2PJ0	Adler et al., 2008
complex with (3-aminomethyl-phenyl)-[((r)-1- benzyloxycarbonylamino-2-methyl-propyl)-hydroxy- phosphinoyloxy]-acetic ac	1.64 Å	2PJ1	2PJ1	2PJ1	2PJ1	2PJ1	2PJ1	Adler et al., 2008
complex with 2-(3-aminomethyl-phenyl)-3-[((r)-1- benzyloxycarbonylamino-2-methyl-propyl)-hydroxy- phosphinoyl]-propioni	1.95 Å	2PJ2	2PJ2	2PJ2	2PJ2	2PJ2	2PJ2	Adler et al., 2008
complex with (3-guanidino-phenyl)-hydroxy-[(r)-2- methyl-1-(3-phenyl-propionylamino)-propyl]-phosphinoyloxy- acetic a	1.64 Å	2PJ3	2PJ3	2PJ3	2PJ3	2PJ3	2PJ3	Adler et al., 2008
complex with [((r)-benzyloxycarbonylamino-cyclohexyl- methyl)-hydroxy-phosphinoyloxy]-(3-guanidino-phenyl)- acetic acid	2.00 Å	2PJ4	2PJ4	2PJ4	2PJ4	2PJ4	2PJ4	Adler et al., 2008
complex with [((r)-1-benzyloxycarbonylamino-hexyl)- hydroxy-phosphinoyloxy]-(3-guanidino-phenyl)-acetic acid complex	1.65 Å	2PJ5	2PJ5	2PJ5	2PJ5	2PJ5	2PJ5	Adler et al., 2008
complex with 2-(3-aminomethyl-phenyl)-3-hydroxy- [(r)-2-methyl-1-(2-phenyl-ethanesulfonylamino)-propyl]- phosphinoyl-	1.60 Å	2PJ6	2PJ6	2PJ6	2PJ6	2PJ6	2PJ6	Adler et al., 2008
complex with 2-(3-aminomethyl-phenyl)-3-[((r)-1- benzenesulfonylamino-2-methyl-propyl)-hydroxy-phosphinoyl]- propionic	1.77 Å	2PJ7	2PJ7	2PJ7	2PJ7	2PJ7	2PJ7	Adler et al., 2008
complex with 2-(3-aminomethyl-phenyl)-3-[(r)-1- (biphenyl-4-sulfonylamino)-2-methyl-propyl]-hydroxy- phosphinoyl-prop	1.70 Å	2PJ8	2PJ8	2PJ8	2PJ8	2PJ8	2PJ8	Adler et al., 2008
complex with 2-(3-aminomethyl-phenyl)-3-[(r)-1- (benzo[1,2,5]thiadiazole-4-sulfonylamino)-2-methyl-propyl]- hydroxy-ph	1.56 Å	2PJ9	2PJ9	2PJ9	2PJ9	2PJ9	2PJ9	Adler et al., 2008
complex with 3-[(r)-1-((s)-2-benzyloxycarbonylamino- 3-phenyl-propionylamino)-2-methyl-propyl]-hydroxy- phosphinoyl-2	1.70 Å	2PJA	2PJA	2PJA	2PJA	2PJA	2PJA	Adler et al., 2008
complex with 2-(3-aminomethyl-phenyl)-3-[1-((s)-2- benzyloxycarbonylamino-3-phenyl-propane-1-sulfonylamino)-2- methyl-	1.70 Å	2PJB	2PJB	2PJB	2PJB	2PJB	2PJB	Adler et al., 2008
complex with ((r)-1-[(s)-2-benzyloxycarbonylamino-3- (4-hydroxy-phenyl)-propionylamino]-2-methyl-propyl- hydroxy-phos	1.74 Å	2PJC	2PJC	2PJC	2PJC	2PJC	2PJC	Adler et al., 2008
zymogen	1.89 Å	3GLJ	3GLJ	3GLJ	3GLJ	3GLJ	3GLJ
in complex with dd2	2.15 Å	3WAB	3WAB	3WAB	3WAB	3WAB	3WAB
complex with dd9	1.70 Å	3WC5	3WC5	3WC5	3WC5	3WC5	3WC5
complex with 2nd zinc	1.65 Å	3WC6	3WC6	3WC6	3WC6	3WC6	3WC6
complex with ef6265	1.90 Å	3WC7	3WC7	3WC7	3WC7	3WC7	3WC7
complex with tafcpb	2.18 Å	4UIA	4UIA	4UIA	4UIA	4UIA	4UIA
complex with tafcpb	1.94 Å	4UIB	4UIB	4UIB	4UIB	4UIB	4UIB
with sulphamoil arginine	1.25 Å	4Z65	4Z65	4Z65	4Z65	4Z65	4Z65
with sulphamoil phenylalanine	1.74 Å	5J1Q	5J1Q	5J1Q	5J1Q	5J1Q	5J1Q
with 2-ND zinc and acetate ion	1.40 Å	5JC6	5JC6	5JC6	5JC6	5JC6	5JC6
complex with anabaenopeptin B	2.02 Å	5LRG	5LRG	5LRG	5LRG	5LRG	5LRG
complex with anabaenopeptin C	2.20 Å	5LRJ	5LRJ	5LRJ	5LRJ	5LRJ	5LRJ
complex with anabaenopeptin F	2.30 Å	5LRK	5LRK	5LRK	5LRK	5LRK	5LRK
crystal structure of 1 in complex with tafcpb	2.02 Å	5LYD	5LYD	5LYD	5LYD	5LYD	5LYD
crystal structure of 1 in complex with tafcpb	2.01 Å	5LYF	5LYF	5LYF	5LYF	5LYF	5LYF
crystal structure of 1 in complex with tafcpb	1.64 Å	5LYI	5LYI	5LYI	5LYI	5LYI	5LYI
crystal structure of 1 in complex with tafcpb	1.83 Å	5LYL	5LYL	5LYL	5LYL	5LYL	5LYL
complex with dd28	1.90 Å	5ZEQ	5ZEQ	5ZEQ	5ZEQ	5ZEQ	5ZEQ